EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Strategic Insight into the Combination Therapies for Metastatic Colorectal Cancer

Yoshihito Kano iD, Mitsukuni Suenaga, Hiroyuki Uetake

Current Oncology · 07.07.2023 · 30 (7) · 6546-6558

DOI: 10.3390/curroncol30070480 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Oncology, online erschienen am 07.07.2023. Verfasst von Yoshihito Kano und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Oncology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo 113-8510, Japan. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Circulating Tumor DNA, Colonic Neoplasms, Rectal Neoplasms. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Colorectal cancer (CRC) is the second most common cause of cancer-related deaths worldwide. The 5-year survival rate after curative resection is almost 80%, however, it is still less than satisfactory for metastatic CRC (mCRC). The combination approach including surgery, chemotherapy, molecular targeted therapy, and immunotherapy is a promising strategy due to its synergistic anticancer effect. Moreover, circulating tumor DNA (ctDNA) analysis has been reported to stratify the post-operative risk of recurrence, thus providing clinically valuable information for deciding to conduct adjuvant chemotherapy. Furthermore, multiple new drugs that potentially target undruggable genes, including KRAS, have been developed. In this review, we discuss the current management of patients with mCRC and future perspectives in the light of a combination therapeutic strategy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsCirculating Tumor DNAColonic NeoplasmsRectal NeoplasmsHumansDNA, Neoplasm

Stichwörter der Autor:innen

KRASG12CRAScombination therapyconversion surgeryliquid biopsymetastatic colorectal cancermolecular targeted therapy

Substanzen

Circulating Tumor DNADNA, Neoplasm

Autor:innen und Institutionen

  • Department of Clinical Oncology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo 113-8510, Japan.
  • Department of Clinical Research, National Hospital Organization Disaster Medical Center, Tokyo 190-0014, Japan.

ORCID-Profile: Yoshihito Kano

Zitieren

APA

Kano, Y., Suenaga, M., & Uetake, H. (2023). Strategic Insight into the Combination Therapies for Metastatic Colorectal Cancer. Current Oncology, 30(7), 6546-6558. https://doi.org/10.3390/curroncol30070480

Vancouver

Kano Y, Suenaga M, Uetake H. Strategic Insight into the Combination Therapies for Metastatic Colorectal Cancer. Current Oncology. 2023;30(7):6546-6558. doi:10.3390/curroncol30070480

BibTeX
@article{Kano2023,
  author = {Kano, Yoshihito and Suenaga, Mitsukuni and Uetake, Hiroyuki},
  title = {Strategic Insight into the Combination Therapies for Metastatic Colorectal Cancer},
  journal = {Current Oncology},
  year = {2023},
  volume = {30},
  number = {7},
  pages = {6546--6558},
  doi = {10.3390/curroncol30070480}
}
Kostenlos starten →